Norcantharidin induces growth inhibition and apoptosis of glioma cells by blocking the Raf/MEK/ERK pathway

World Journal of Surgical Oncology

Volumn 12, Issue 1, 2014, Pages

  Zheng, Jie ^a   Du, Wei ^b   Song, Lai jun ^b   Zhang, Rui ^a   Sun, Lai guang ^a   Chen, Feng guo ^a   Wei, Xin ting ^b  

^a XINXIANG CENTRAL HOSPITAL   (China)

^b THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

Author keywords

Apoptosis; Glioma; MAPK; Norcantharidin

Indexed keywords

ARYLAMINE ACETYLTRANSFERASE; FUSED HETEROCYCLIC RINGS; MAP2K1 PROTEIN, HUMAN; MAPK1 PROTEIN, HUMAN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; NORCANTHARIDIN; PROTEIN BAX; PROTEIN BCL 2; RAF PROTEIN;

ANIMAL; ANTAGONISTS AND INHIBITORS; APOPTOSIS; BRAIN NEOPLASMS; CELL CYCLE; CELL PROLIFERATION; DRUG EFFECTS; FLOW CYTOMETRY; GLIOMA; HUMAN; METABOLISM; MOUSE; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL CULTURE; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; ARYLAMINE N-ACETYLTRANSFERASE; BCL-2-ASSOCIATED X PROTEIN; BICYCLO COMPOUNDS, HETEROCYCLIC; BLOTTING, WESTERN; BRAIN NEOPLASMS; CELL CYCLE; CELL PROLIFERATION; FLOW CYTOMETRY; GLIOMA; HUMANS; MAP KINASE KINASE 1; MICE; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; PROTO-ONCOGENE PROTEINS C-BCL-2; RAF KINASES; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED;

EID: 84904915678     PISSN: None     EISSN: 14777819     Source Type: Journal    
DOI: 10.1186/1477-7819-12-207     Document Type: Article

References (21)

1. Mannas JP, Lightner DD, Defrates SR, Pittman T, Villano JL. Long-term treatment with temozolomide in malignant glioma. J Clin Neurosci 2014, 21:121-123. 10.1016/j.jocn.2013.03.039, 24063865.
2. Scaringi C, Enrici RM, Minniti G. Combining molecular targeted agents with radiation therapy for malignant gliomas. Oncol Targets Ther 2013, 6:1079-1095.
3. Yan W, Zhang W, Jiang T. Oncogene addiction in gliomas: implications for molecular targeted therapy. J Exp Clin Cancer Res 2011, 30:58. 10.1186/1756-9966-30-58, 3113747, 21575270.
4. Gao Q, Lei T, Ye F. Therapeutic targeting of EGFR-activated metabolic pathways in glioblastoma. Expert Opin Investig Drugs 2013, 22:1023-1040. 10.1517/13543784.2013.806484, 23731170.
5. Kondo Y, Hollingsworth EF, Kondo S. Molecular targeting for malignant gliomas (Review). Int J Oncol 2004, 24:1101-1109.
6. Wong KK. Recent developments in anti-cancer agents targeting the Ras/Raf/MEK/ERK pathway. Recent Pat Anticancer Drug Discov 2009, 4:28-35. 10.2174/157489209787002461, 19149686.
7. Thompson N, Lyons J. Recent progress in targeting the Raf/MEK/ERK pathway with inhibitors in cancer drug discovery. Curr Opin Pharmacol 2005, 5:350-356. 10.1016/j.coph.2005.04.007, 15955734.
8. Shen B, He PJ, Shao CL. Norcantharidin induced DU145 cell apoptosis through ROS-mediated mitochondrial dysfunction and energy depletion. PLoS One 2013, 8:e84610. 10.1371/journal.pone.0084610, 3868658, 24367681.
9. Zhang J, Tang Y, Li S, Liao C, Guo X. Targeting of the B-lineage leukemia stem cells and their progeny with norcantharidin encapsulated liposomes modified with a novel CD19 monoclonal antibody 2E8 in vitro. J Drug Target 2010, 18:675-687. 10.3109/10611861003649720, 20222850.
10. Chang C, Zhu Y, Tang X, Tao W. The anti-proliferative effects of norcantharidin on human HepG2 cells in cell culture. Mol Biol Rep 2011, 38:163-169. 10.1007/s11033-010-0090-6, 20333548.
11. Zhang S, Li G, Ma X, Wang Y, Liu G, Feng L, Zhao Y, Zhang G, Wu Y, Ye X, Qin B, Lu J. Norcantharidin enhances ABT-737-induced apoptosis in hepatocellular carcinoma cells by transcriptional repression of Mcl-1. Cell Signal 2012, 24:1803-1809. 10.1016/j.cellsig.2012.05.009, 22609455.
12. Yu CC, Ko FY, Yu CS, Lin CC, Huang YP, Yang JS, Lin JP, Chung JG. Norcantharidin triggers cell death and DNA damage through S-phase arrest and ROS-modulated apoptotic pathways in TSGH 8301 human urinary bladder carcinoma cells. Int J Oncol 2012, 41:1050-1060.
13. Cimmino F, Scoppettuolo MN, Carotenuto M, De Antonellis P, Dato VD, De Vita G, Zollo M. Norcantharidin impairs medulloblastoma growth by inhibition of Wnt/beta-catenin signaling. J Neurooncol 2012, 106:59-70. 10.1007/s11060-011-0645-y, 21735115.
14. Lo HW. Targeting Ras-RAF-ERK and its interactive pathways as a novel therapy for malignant gliomas. Curr Cancer Drug Targets 2010, 10:840-848. 10.2174/156800910793357970, 3615246, 20718706.
15. Zhang L, Ji Q, Liu X, Chen X, Chen Z, Qiu Y, Sun J, Cai J, Zhu H, Li Q. Norcantharidin inhibits tumor angiogenesis via blocking VEGFR2/MEK/ERK signaling pathways. Cancer Sci 2013, 104:604-610. 10.1111/cas.12120, 23363445.
16. Yang TM, Barbone D, Fennell DA, Broaddus VC. Bcl-2 family proteins contribute to apoptotic resistance in lung cancer multicellular spheroids. Am J Respir Cell Mol Biol 2009, 41:14-23. 10.1165/rcmb.2008-0320OC, 2701959, 19097992.
17. Yip KW, Reed JC. Bcl-2 family proteins and cancer. Oncogene 2008, 27:6398-6406. 10.1038/onc.2008.307, 18955968.
18. Vitagliano O, Addeo R, D'Angelo V, Indolfi C, Indolfi P, Casale F. The Bcl-2/Bax and Ras/Raf/MEK/ERK signaling pathways: implications in pediatric leukemia pathogenesis and new prospects for therapeutic approaches. Expert Rev Hematol 2013, 6:587-597. 10.1586/17474086.2013.827415, 24083449.
19. Rieger L, Weller M, Bornemann A, Schabet M, Dichgans J, Meyermann R. BCL-2 family protein expression in human malignant glioma: a clinical-pathological correlative study. J Neurol Sci 1998, 155:68-75. 10.1016/S0022-510X(97)00277-3, 9562325.
20. Chang C, Zhu YQ, Mei JJ, Liu SQ, Luo J. Involvement of mitochondrial pathway in NCTD-induced cytotoxicity in human hepG2 cells. J Exp Clin Cancer Res 2010, 29:145. 10.1186/1756-9966-29-145, 2987898, 21059274.
21. Kok SH, Cheng SJ, Hong CY, Lee JJ, Lin SK, Kuo YS, Chiang CP, Kuo MY. Norcantharidin-induced apoptosis in oral cancer cells is associated with an increase of proapoptotic to antiapoptotic protein ratio. Cancer Lett 2005, 217:43-52. 10.1016/j.canlet.2004.07.045, 15596295.